Page last updated at 06:44 GMT, Wednesday, 29 April 2009 07:44 UK

Over-40s may benefit from aspirin

Aspirin
Regular aspirin use has been linked to abdominal bleeds.

Taking aspirin in your 40s could cut the risk of cancer later in life, a review of research suggests.

Experts said taking the drug at an age before cancer usually develops, and for ten years would maximise its potential to prevent the disease.

Aspirin has been linked to a reduced risk of some cancers, and heart disease, but also to a raised risk of ulcers and internal bleeding.

The Cancer Research UK study features in the journal Lancet Oncology.

Many questions need to be answered before we would advise regular use of aspirin for cancer prevention.
Professor Jack Cuzick
Cancer Research UK Centre for Epidemiology

Aspirin blocks the effects of proteins which can trigger inflammation, and which are found at unusually high levels in several types of cancer.

Previous research suggests people who take the drug are less likely to develop bowel, breast and possibly some other types of cancer.

However, regular use of aspirin specifically for cancer prevention is not currently recommended because of the risk of side effects.

Common cancers, such as prostate, breast, lung and bowel, tend to develop after the age of 60 - when the risk of aspirin causing internal bleeding is at its highest.

Lead researcher Professor Jack Cuzick, from the Cancer Research UK Centre for Epidemiology at Queen Mary, University of London, said pre-cancerous lesions tended to start developing in the mid-40s.

Thus, taking aspirin around that time may be the best strategy for preventing that damage progressing to the full-blown disease.

It would also carry a much lower risk of side effects than beginning to take aspirin 15-20 years later.

Work needed

However, Professor Cuzick said: "Many questions need to be answered before we would advise regular use of aspirin for cancer prevention.

"Future research and more clinical trials are needed to better identify those people who are at high risk of developing cancers and at low risk of side effects, who will benefit most from aspirin treatment."

Professor Cuzick said it was not clear a lower dose "baby aspirin" could achieve the same anti-cancer effect as the standard dose of 300mg/day.

The researchers also found that taking aspirin in combination with other drugs known as proton pump inhibitors could help to lower the risk of stomach bleeding.

Dr Lesley Walker, Cancer Research UK's director of cancer information, said: "It's too soon to recommend that people take aspirin to try and stop cancer developing because of the side effects.

"It's important that any decision to take aspirin regularly is only made in consultation with a GP."

Ellen Mason, of the British Heart Foundation (BHF), also stressed it was too early for researchers to recommend taking aspirin to reduce the risk of cancer.

"Currently the risk of bleeding outweighs the benefit," she said.

"Many thousands of people in the UK are prescribed aspirin because they have heart disease.

"This research does not prove that they will also get protection from cancer at a low dose, but as they already need to take aspirin it would be reassuring if further research eventually shows an anti-cancer benefit."



Print Sponsor


SEE ALSO
Aspirin cuts stomach cancer risk
06 Feb 09 |  Health
Daily aspirin in middle-age call
23 Aug 08 |  Health
Aspirin 'could cut liver damage'
27 Jan 09 |  Health
Aspirin may increase stroke risk
01 May 07 |  Health

RELATED INTERNET LINKS
The BBC is not responsible for the content of external internet sites


FEATURES, VIEWS, ANALYSIS
Has China's housing bubble burst?
How the world's oldest clove tree defied an empire
Why Royal Ballet principal Sergei Polunin quit

BBC navigation

BBC © 2014 The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.

Americas Africa Europe Middle East South Asia Asia Pacific